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Abstract 
Interleukin (IL)-22 regulates tissue inflammation and repair. Here we report participation of the liver in 
IL-22-mediated cardiac repair after acute myocardial infarction (MI).  
Methods: We induced experimental MI in mice by ligation of the left ascending artery and evaluated the effect 
of IL-22 on post-MI cardiac function and ventricular remodeling.  
Results: Daily subcutaneous injection of 100 µg/kg mouse recombinant IL-22 for seven days attenuated 
adverse ventricular remodeling and improved cardiac function in mice at 28 days after left anterior descending 
coronary artery ligation-induced MI. Pharmacological inhibition of signal transducer and activator of 
transcription (STAT3) muted these IL-22 activities. While cardiomyocyte-selective depletion of STAT3 did not 
affect IL-22 activities in protecting post-MI cardiac injury, hepatocyte-specific depletion of STAT3 fully muted 
these IL-22 cardioprotective activities. Hepatocyte-derived fibroblast growth factor (FGF21) was markedly 
increased in a STAT3-dependent manner following IL-22 administration and accounted for the 
cardioprotective benefit of IL-22. Microarray analyses revealed that FGF21 controlled the expression of 
cardiomyocyte genes that are involved in cholesterol homeostasis, DNA repair, peroxisome, oxidative 
phosphorylation, glycolysis, apoptosis, and steroid responses, all of which are responsible for cardiomyocyte 
survival.  
Conclusions: Supplementation of IL-22 in the first week after acute MI effectively prevented left ventricular 
dysfunction and heart failure. This activity of IL-22 involved crosstalk between the liver and heart after 
demonstrating a role of the hepatic STAT3-FGF21 axis in IL-22-induced post-MI cardiac protection. 
Key words: IL-22, myocardial infarction, liver-heart crosstalk, FGF21 
Introduction 
In the past decades, advances in early 
reperfusion therapies have reduced mortality in 
patients with myocardial infarction (MI) [1]. However, 
post-MI heart failure remains a significant clinical 
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challenge for patients who survive MI. The 
pathogenesis of post-MI heart failure is associated 
with a chronic maladaptive process referred to as 
ventricular remodeling [2]. Despite the availability of 
multiple treatments to target ventricular remodeling, 
e.g., β-blockers and angiotensin-converting enzyme 
inhibitors, the incidence of post-MI heart failure has 
increased and led to a high mortality rate and poor life 
quality [3]. Therefore, the search for alternative 
management strategies targeting ventricular 
remodeling remains of major clinical importance. 
Interleukin (IL)-22, a member of the IL-10 
cytokine family, is an important regulator of 
inflammation and tissue repair and is produced 
mainly by innate lymphoid cells, CD4+ T cells, and 
natural killer cells [4]. IL-22 exerts its function by 
binding to IL-22 receptor 1 (IL-22R1) and IL-10R2 [5]. 
Of the two receptors, IL-10R2 shows ubiquitous 
expression, whereas IL-22R1 has selective expression 
and determines the IL-22 target cells. Accumulating 
evidence suggests that IL-22 protects tissue from 
damage and enhances tissue repair during the 
inflammatory process by activating signal transducer 
and activator of transcription (STAT3) [6-10]. At 
present, a phase 2, open-label study (NCT02655510) is 
being conducted to assess the efficacy and safety of a 
recombinant protein containing human IL-22 and 
immunoglobulin G2-Fc (F-652) in alcoholic hepatitis 
patients. Administration of IL-22 is associated with 
tissue protection and repair in murine models of liver 
[11] and kidney [12] ischemic injuries. The heart also 
expresses IL-22 R1 [13], yet the contribution of IL-22 to 
post-MI cardiac inflammation and repair remains 
unknown. 
Fibroblast growth factor (FGF21) belongs to the 
FGF superfamily and is expressed predominantly in 
the liver [14]. Early studies identified FGF21 as a 
hepatokine that is induced in response to stresses, 
such as cold exposure, starvation, and mitochondrial 
stress, and that regulates lipid, glucose, and energy 
metabolism [15-17]. More recent studies have 
indicated a role for FGF21 in cardiovascular stress and 
diseases. FGF21 knockout (KO) mice showed worse 
cardiac function with a hypertrophic stimulus, which 
could be ameliorated by treatment with FGF21 [18]. 
FGF21 administration significantly preserved cardiac 
function post-MI [19]. Here we report a protective role 
of IL-22 in post-MI cardiac injury via liver-derived 
FGF21 following hepatic STAT3 activation.  
Methods 
Animals 
Male C57BL/6J mice aged 8-10 weeks were 
purchased from Peking University (Beijing, China). 
Cardiac-specific STAT3 KO mice (αMHC- 
MerCreMer/STAT3flox/flox) were generated by 
breeding STAT3flox/flox mice (from Jackson Laboratory, 
USA) with αMHC-MerCreMer mice (from Dr. 
Hongliang Li, Renmin Hospital of Wuhan University, 
China). To induce Cre-mediated recombination, 
αMHC-MerCreMer mice or αMHC-MerCreMer/ 
STAT3flox/flox mice were intraperitoneally injected 
with 20 mg/kg tamoxifen (Sigma, USA) daily for 5 
consecutive days. Liver-specific STAT3 KO mice 
(ALB-Cre/STAT3flox/flox) were provided by Dr. 
Zhexiong Lian, University of Science and Technology 
of China, China. Liver-specific FGF21 KO 
(ALB-Cre/FGF21flox/flox) mice were obtained from Dr. 
Aimin Xu, University of Hong Kong, China. All 
genetically engineered mice were on a C57BL/6J 
background. All animal studies were conducted 
according to the criteria outlined in the “Guide for the 
Care and Use of Laboratory Animals” prepared by the 
National Academy of Sciences and published by the 
National Institute of Health (NIH publication 86-23 
revised 1985) and approved by the Animal Care and 
Utilization Committee of Huazhong University of 
Science and Technology, China. 
MI and study design 
MI was produced by ligating the left anterior 
descending coronary artery as described previously 
[20]. In brief, after anesthesia with ketamine (75 
mg/kg) and medetomidine (1 mg/kg), mice were 
intubated and ventilated on a rodent respirator. 
Parasternal thoracotomy was performed and the left 
anterior descending coronary artery was visualized 
and ligated at a level approximately 3 mm from its 
origin using an 8-0 silk suture. Mice in the sham 
group underwent the same procedure except for the 
coronary artery ligation. All the operations in this 
study were performed by an experienced and skilled 
surgeon who was blinded to the experimental groups. 
Recombinant mouse IL-22 (derived from Escherichia 
coli, purity> 95% by SDS-PAGE and endotoxin level 
<1.09 EU/mg), provided by Generon (Shanghai, 
China) Corporation Ltd. [21], was dissolved in 1% 
mouse serum in phosphate-buffered saline (PBS) or 
an equal volume of 1% serum in PBS and injected 
subcutaneously daily for 7 days at a dose of 100 
μg/kg immediately after the operation. In the STAT3 
inhibitor experiment, the STAT3 inhibitor S3I-201 
(Merck, Germany) was administered intraperitoneally 
at a dose of 5 mg/kg every 2 days from 1day prior to 
the coronary artery ligation until 6 days after the 
ligation [22]. 
Echocardiographic and hemodynamic analysis  
Transthoracic echocardiography was performed 
using a Vevo 2100 high-resolution microimaging 
system (VisualSonics, Canada) on lightly sedated 
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mice (with 2% isoflurane) before the operation and at 
day 28 post-MI. Two-dimensional echocardiographic 
views of the mid-ventricular short axis and 
parasternal long axis were obtained for guided 
M-mode measurements of the left ventricular 
end-diastolic diameter (LVEDD), left ventricular 
end-systolic diameter (LVESD), fractional shortening 
(FS) and ejection fraction (EF). Echocardiographic 
acquisition and analysis were performed by a 
technician who was blinded to the treatment groups. 
For hemodynamic measurements, a 1.4 French 
micromanometer-tipped catheter (SPR-671, Millar 
Instruments, USA) was inserted into the right carotid 
artery and then advanced into the LV. Left ventricular 
end-diastolic pressure (LVEDP) was measured, and 
the maximal (LV +dp/dtmax.) and minimal (LV 
-dp/dtmin.) first derivative of the LV pressure rise and 
fall were calculated.  
Statistics 
Data are expressed as the mean ± SEM. 
Differences were evaluated using unpaired Student’s 
t-test or chi-square test between two groups and 
one-way ANOVA followed by a post hoc 
Student-Newman-Keuls test for multiple 
comparisons. All analyses were performed using SPSS 
13.0, and p<0.05 was considered statistically 
significant.  
Additional methods 
Detailed methods are provided in 
Supplementary Material. 
Results  
Recombinant IL-22 improves post-MI survival 
and cardiac function  
We first examined the expression of the IL-22 
receptors IL-22R1 and IL-10R2 in different tissues. 
RT-PCR and immunoblot analysis showed low levels 
of both receptors in mouse hearts and aortas, but high 
levels of IL-22R1 and IL-10R2 in mouse livers (Figure 
S1A-C). Further evaluation of heart resident cells 
showed expression of IL-22R1 and IL-10R2 in 
hepatocytes but negligible expression in 
cardiomyocytes, cardiac fibroblasts, endothelial cells, 
and lymphocytes (Figure S1D-G). To directly 
evaluate the role of IL-22 in ventricular remodeling, 
we gave a subcutaneous injection of recombinant 
IL-22 (100 μg‧kg-1‧d-1) or saline to wild type (WT) mice 
immediately after MI production for 7 consecutive 
days. Cardiac function was assessed by 
echocardiography and cardiac catheterization at 28 
days post-MI. Injection of IL-22 significantly increased 
the plasma IL-22 levels, reaching a peak concentration 
of 6545.84±1277.90 pg/mL at 1 h and returning to the 
baseline at 12 h after administration (Figure S2). 
Seven days of injection of IL-22 resulted in a 
significant improvement in post-MI survival (Figure 
1A). And, recombinant IL-22 improved post-MI 
cardiac function, as evidenced by decreased LVEDD, 
LVESD, and LVEDP and increased FS, EF, 
+dp/dtmax and -dp/dtmin in IL-22-treated mice 
compared with those in the saline-treated control 
mice (Figure 1B-I and Table S1).  
 
 
Figure 1. IL-22 protects mice from post-MI cardiac injury. (A) Survival curves of sham mice (n=12), MI mice (n=85), saline-treated MI mice (n=62), and IL-22-treated MI 
mice (n=50) groups at 28 days after operation. (B) Representative M-mode echocardiographic images at 28 days after operation. (C-I) Quantification of LVEDD, LVESD, FS and 
EF by echocardiography, and LVEDP, dp/dtmax, and dp/dtmin by hemodynamic analysis at 28 days after operation. n=10-15 per group. #p<0.05 by log-rank (Mantel-Cox) test in 
(A) and*p<0.05 vs. Sham group and #p<0.05 vs. MI+Saline group by one-way ANOVA in (C-I). 
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Figure 2. IL-22 decreases post-MI infarct size and fibrosis and promotes post-MI neovascularization. (A) Representative images of Masson’s trichrome-stained 
heart sections (scale: 2000 μm) and (B) quantification of infarct size at 28 days post-MI. n=8-10 per group. (C) Representative images of Masson’s trichrome-stained heart 
sections (scale: 100 μm) at 28 days post-MI and (D) quantification of interstitial fibrosis by collagen volume fraction per high-magnification view. n=8-10 per group. (E) 
Representative immunostaining of CD31+ cells in the peri-infarct zone (scale:100 μm) on heart sections at 3 days post-MI and (F) the calculated CD31+ cell number per 
high-magnification view. n=8 per group. *p<0.05 vs. MI+Saline group by one-way ANOVA. 
 
After demonstrating the cardiac protection of 
IL-22 against MI, we assessed IL-22 activities in 
cardiac necrosis, fibrosis, neovascularization, and 
inflammatory cell profiles in ventricular remodeling. 
Heart infarct size and interstitial fibrosis were 
determined at 28 days post-MI by Masson’s trichrome 
staining. Interstitial fibrosis was analyzed as the 
collagen volume fraction in the border zone. Border 
zone neovascularization was evaluated by CD31 
staining at 3 days post-MI. Infarct size (Figure 2A-B) 
and collagen volume fraction (Figure 2C-D) 
decreased significantly in IL-22-treated mice 
compared with saline-treated control mice. We 
detected a marked increase in the number of 
CD31-positive capillaries in IL-22-treated mice 
(Figure 2E-F). Flow cytometry was used to analyze 
the impact of IL-22 administration on the infiltration 
of leukocytes in the heart at 3 and 7 days post-MI. 
Figure 3A shows the identification of leukocytes as 
CD45-positive cells and the definition of different 
leukocyte populations by their specific surface 
markers. IL-22 inhibited the infiltration of total 
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leukocytes, neutrophils, monocytes/macrophages, 
natural killer cells, γδ T cells, and B cells while 
promoting the infiltration of αβ T cells (Figure 3B-H). 
Previous studies have reported that decreased 
accumulation of monocytes/macrophages [23], 
neutrophils [24], γδT cells [25] and B cells [26] in the 
infarcted heart was associated with improved cardiac 
dysfunction post-MI, while a deficiency of CD4+ T 
cells [27], which accounted for the majority of αβT 
cells in the infarcted heart, was associated with a 
worse outcome post-MI. Therefore, the altered 
accumulation of leukocytes after IL-22 treatment may 
be associated with improved post-MI cardiac function 
in IL-22-treated mice. 
 
 
 
Figure 3. IL-22 inhibits post-MI cardiac inflammation. (A) Gating strategy for infiltrated CD45+ total leukocytes, CD45+CD11b+F4/80+ macrophages, 
CD45+CD11b+Ly6G+ neutrophils, CD45+CD11b-CD3+γδTCR- αβT cells, CD45+CD11b-CD3+ γδ TCR+ γδT cells, CD45+CD11b-NKp46+ natural killer (NK) cells, and 
CD45+CD11b-CD19+ B cells in the heart. (B-H) Quantification of the absolute numbers of different infiltrated inflammatory cells per gram of heart. n=5 per group. *p<0.05 vs 
Sham group and #p<0.05 vs. MI+Saline group by one-way ANOVA. 
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Figure 4. IL-22 protects mice post-MI cardiac injury via STAT3 activation. (A) Representative M-mode echocardiographic images at 28 days after operation. (B-E) 
Analysis of LVEDD, LVESD, FS and EF by echocardiography at 28 days after operation. n=8-10 per group. (F-H) Quantification of LVEDP, dp/dtmax, and dp/dtmin by 
hemodynamic analysis at 28 days after operation. n=8 per group. *p<0.05 vs Sham group and #p<0.05 vs. MI+Saline group by one-way ANOVA. 
 
IL-22 protects the heart against MI via hepatic 
but not cardiac STAT3 activation  
The functional link between IL-22 and STAT3 
activation is known in liver injury and intestinal 
inflammation [6-10]. It is possible that IL-22-mediated 
post-MI cardiac injury protection also involved 
STAT3 activation. We tested this hypothesis by giving 
MI mice a STAT3 inhibitor S3I-201 [28]. We first 
confirmed that S3I-201 effectively inhibited 
phosphorylation of STAT3 in vivo (Figure S3). S3I-201 
led to cardiac function deterioration and diminished 
the IL-22 post-MI cardioprotective activities (Figure 
4A-H and Table S2). However, when attempting to 
explore how IL-22 modulated post-MI cardiac STAT3 
activation and to identify its target cells in the heart, 
we could not detect cardiac STAT3 activation in vivo 
in IL-22-treated mice (Figure 5A). Similarly, we were 
unable to observe STAT3 activation in either 
cardiomyocytes or cardiac fibroblasts after they were 
subjected to in vitro IL-22 treatment (Figure 5B). To 
identify the possible intrinsic links between cardiac 
STAT3 activation and IL-22-mediated post-MI 
cardioprotection, we generated cardiac-specific 
STAT3 KO mice by breeding α-MHC-MerCreMer 
mice with STAT3flox/flox mice. Consistent with prior 
studies [29], cardiac-specific STAT3 ablation 
exacerbated post-MI cardiac dysfunction. However, 
IL-22 administration retained its activity in improving 
post-MI cardiac function in cardiac-specific STAT3 
KO mice (Figure 5C, Figure S4 and Table S3), as in 
WT control mice (Figure 1B-I), suggesting that cardiac 
STAT3 activation was not required for IL-22-mediated 
post-MI cardioprotection. 
IL-22 is known to induce prominent hepatic 
STAT3 activation [30]. We assessed changes in hepatic 
STAT3 activation in IL-22-treated mice after MI. IL-22 
induced rapid and transient hepatic STAT3 activation 
in mice with MI in vivo, reaching maximum activation 
within 30 min after IL-22 administration and 
returning to the baseline in 3 h (Figure 5D). 
Furthermore, IL-22 treatment induced STAT3 
activation in primary cultured hepatocytes (Figure 
5E). To examine the role of hepatic STAT3 activation 
in IL-22-mediated cardiac protection, we generated 
liver-specific STAT3 KO mice by breeding ALB-Cre 
mice with STAT3flox/flox mice. Unexpectedly, 
liver-specific STAT3 deletion exacerbated cardiac 
dysfunction and abolished the protective effects of 
IL-22 on cardiac function post-MI (Figure 5F, Figure 
S5 and Table S4). These in vitro and in vivo 
observations suggest that hepatic but not cardiac 
STAT3 activation is essential for the beneficial effect of 
IL-22 on post-MI cardiac function.  
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Figure 5. The cardioprotective effect of IL-22 depends on hepatic STAT3 activation. (A) Quantification of STAT3 phosphorylation in the heart at different time 
points post-MI by ELISA. n=5 per group. (B) Representative western blot images of STAT3 phosphorylation in cardiomyocytes and cardiac fibroblasts treated with IL-22 at 
different time points. (C) Analysis of LVEDD, LVESD, FS and EF by echocardiography at 28 days post-MI. n=8 per group. (D) Quantification of STAT3 phosphorylation in the liver 
at different time points post-MI by ELISA. n=5 per group. (E) Representative western blot images of STAT3 phosphorylation in IL-22- stimulated primary hepatocytes at different 
time points. (F) Analysis of LVEDD, LVESD, FS and EF by echocardiography at 28 days post-MI. n=8 per group. *p<0.05 by unpaired t test in (D) and by one-way ANOVA in (C, 
F). 
 
IL-22 protects post-MI cardiac dysfunction via 
liver-derived FGF21  
The role of IL-22 in liver-specific STAT3 
activation (Figure 5E-F) inspired us to identify the 
molecules from hepatic STAT3 activation that mediate 
the cardioprotective effects of IL-22. We compared the 
liver expression levels between IL-22-treated and 
control mice of ten common genes that are regulated 
by IL-22 [31] or are cardioprotective [32], namely, 
alpha-1-acid glycoprotein-2 (AGP2), AGP3, C-X-C 
ligand-13 (CXCL13), FGF21, trefoil factor-3 (TFF3), 
lipopolysaccharide binding protein (LBP), 
neuregulin-4 (NRG4), proteoglycan-4 (PRG4), BMP 
binding endothelial regulator (BMPER), and serum 
amyloid A-2 (SAA2). Of the ten genes, only the 
mRNA levels of FGF21 and AGP2 were elevated 
significantly at 6-12 h after IL-22 treatment (Figure 
S6). Immunoblot analysis examined the protein levels 
of FGF21 and AGP2 in livers from mice at 12 h 
post-MI. MI increased liver FGF21 protein levels, and 
IL-22 further increased liver FGF21 expression. These 
increases were more robust than those of AGP2 
(Figure 6A). Plasma FGF21 levels were also markedly 
elevated in mice at 12 h post-MI. IL-22 administration 
further increased plasma FGF21 levels at 12 and 24 h 
post-MI (Figure 6B). FGF21 is also inducible in many 
organs, such as white and brown adipose tissue, 
pancreas, skeletal muscle, heart and kidney [33]. 
However, RT-PCR did not detect an effect of IL-22 on 
FGF21 expression in the heart, pancreas, kidney, 
brown adipose tissue, white adipose tissue, or skeletal 
muscle (Figure S7). 
The absences of IL-22 cardioprotection in 
liver-selective STAT3 KO mice (Figure 5F), 
IL-22-induced STAT3 activation in the liver and 
hepatocytes (Figure 5D-E), and IL-22-induced liver 
FGF21 expression (Figure S6 and Figure 6A) all 
suggest a role of IL-22 in inducing liver FGF21 
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expression via STAT3 activation. We tested this 
hypothesis by showing that IL-22 activity in inducing 
plasma FGF21 levels was blunted in mice with 
liver-specific STAT3 ablation (Figure 6C). In cultured 
mouse hepatocytes, immunoblot analysis demonstra-
ted that IL-22 activated STAT1, STAT3, and ERK1/2 
(Figure S8A). However, FGF21 secretion was blocked 
by only the STAT3 inhibitor S3I-201, not the STAT1 
inhibitor fludarabine or the ERK inhibitor PD98059 
(Figure S8B). 
To test the role of liver-derived FGF21 in 
IL-22-mediated post-MI cardioprotection, we 
generated liver-specific FGF21 KO mice by breeding 
ALB-Cre mice with FGF21flox/flox mice. Plasma FGF21 
levels decreased in liver-specific FGF21 KO mice 
(Figure S9), and these mice showed poorer cardiac 
function than control mice (Figure 6D). 
Administration of IL-22 improved cardiac function in 
these liver-specific FGF21 KO mice, but these 
improvements were much weaker than those in 
IL-22-treated FGF21flox/flox control mice (Figure 6D, 
Figure S10 and Table S5). These observations suggest 
the following: liver FGF21 played a cardioprotective 
role, as previously found [32], because ALB-Cre/ 
FGF21flox/flox mice showed impaired cardiac function; 
IL-22 protected post-MI cardiac dysfunction via 
liver-specific FGF21 because the cardiac function in 
IL-22-treated ALB-Cre/FGF21flox/flox mice did not 
 
 
Figure 6. IL-22 promotes liver FGF21 production to protect mice from post-MI cardiac injury. (A) Representative western blot images of FGF21 and AGP2 
protein in the liver at 12 hours post-MI. (B) ELISA-determined plasma FGF21 levels in sham, saline-treated, and IL-22-treated mice at 12 h and 24 h post-MI. (C) Comparison 
of plasma FGF21 levels by ELISA between WT and ALB-Cre/STAT3flox/flox mice in basal condition or at 12 h post-MI treated with saline or IL-22. n=5-10 per group. (D) Analysis 
of LVEDD, LVESD, FS and EF by echocardiography at 28 days post-MI. n=8-12 per group. (E) Representative western blot images of FGFR1, FGFR2, FGFR3, FGFR4 and β-klotho 
in cardiomyocytes (left panels) and representative coimmunoprecipitation images of FGFR1 and tyrosine phosphorylation in cardiomyocytes stimulated with FGF21 for 20 min 
(right panels). (F) Heat map of genes involved in lipid biosynthesis and differentially regulated by FGF21 in hypoxic cardiomyocytes. Red represents upregulation and blue 
represents downregulation. (G) GO analysis of biological processes that are enriched in FGF21-treated cardiomyocytes. *p<0.05 by unpaired t-test in (B-C) and by one-way 
ANOVA in (D). 
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reach the same level as that in IL-22-treated 
FGF21flox/flox control mice; and, FGF21 was not the 
only contributor to the cardioprotective effects of 
IL-22, because IL-22 administration did not 
completely lose its cardioprotective activity in 
liver-specific FGF21 KO mice. Therefore, IL-22 must 
also have a liver FGF21-independent cardioprotective 
function, which is a hypothesis that merits further 
investigation. To determine whether FGF21 acted 
directly on the heart, we performed immunoblot 
analysis and found that cardiomyocytes expressed all 
FGF21 receptors, including FGFR1, FGFR2, FGFR3, 
FGFR4, and its coreceptor β-klotho. Coimmuno-
precipitation revealed FGFR1 activation (tyrosine 
phosphorylation) in FGF21-treated cardiomyocytes 
(Figure 6E), suggesting that FGFR1 is a functional 
receptor of FGF21 in cardiomyocytes.  
FGF21 changes the expression of genes 
responsible for cardiomyocyte survival 
To further explore the cardioprotective role of 
FGF21, we treated mouse cardiomyocytes with and 
without FGF21 under normoxic or hypoxic conditions 
to mimic those of MI injury. The majority of genes 
regulated by FGF21 in hypoxic cardiomyocytes were 
those involved in lipid metabolism, which were 
inhibited under hypoxic conditions (Figure 6F). In 
addition, FGF21 changed the expression of genes 
related to several other aspects of hypoxic 
cardiomyocytes, including ion homeostasis and cell 
proliferation and apoptosis (Table S6). Gene ontology 
(GO) analysis demonstrated that the top 10 ranked 
FGF21-controlled biological processes were mostly 
related to lipid biosynthesis and metabolism (Figure 
6G). To gain more insights into the pathobiological 
significance of our findings, we performed gene set 
enrichment analysis (GSEA) to evaluate the data at 
the level of gene sets [34]. We found that hypoxic 
cardiomyocytes treated with FGF21 are enriched in 
gene sets pertaining to cholesterol homeostasis, DNA 
repair, peroxisome, oxidative phosphorylation, 
glycolysis, apoptosis, and steroid responses (Table 
S7). Microarray data were verified by RT-PCR on 
select genes with known functions that are listed in 
Table S6. RT-PCR validated the upregulation of genes 
involved in cholesterol synthesis (Acly, Lss, and Sqle) 
and cholesterol transport (Stard4 and Ldlr). In 
addition, the upregulation of Dhcr24, which has been 
shown to catalyze the reduction of the delta-24 double 
bond of sterol intermediates during cholesterol 
biosynthesis and to be antiapoptotic via interaction 
with p53 [35], was found. The down-regulation of 
Kcne3, which is linked to potassium channel activity, 
was also observed. Intrigued by our finding that 
FGF21-regulated genes are related to several 
biological processes (Figure S11A), we asked whether 
FGF21 affects cardiomyocyte survival under hypoxic 
conditions. We found that FGF21 reduced caspase-3 
activity in hypoxic cardiomyocytes (Figure S11B), 
demonstrating that FGF21 can inhibit apoptosis. 
Discussion  
This study established a post-MI 
cardioprotective role of IL-22 via hepatic STAT3 
activation and FGF21 secretion independent of 
cardiac STAT3 activation. We used cardiac-specific 
STAT3 KO, liver-specific STAT3 KO, and 
liver-specific FGF21 KO mice to confirm these 
unexpected observations. Mechanistic studies 
disproved a direct role of IL-22 in cardiac resident 
cells, likely due to their low expression of IL-22 
receptors, but established an indirect role of IL-22 in 
cardiomyocytes via hepatic FGF21 on the expression 
of cholesterol homeostasis, DNA repair, peroxisome, 
oxidative phosphorylation, glycolysis, apoptosis, and 
steroid responses genes that are essential to 
cardiomyocyte survival. 
Clinical studies have reported an association 
between liver dysfunction and heart failure in 
humans, but the underlying mechanisms have never 
been understood. Patients with cirrhosis, a condition 
with impaired liver function, are at high risk for heart 
failure characterized by impaired systolic/diastolic 
function and electrophysiological abnormalities, 
termed “cirrhotic cardiomyopathy” [36]. A post hoc 
analysis of the EVEREST (Efficacy of Vasopressin 
Antagonism in Heart Failure Outcome Study with 
Tolvaptan) trial indicates that markers of liver 
dysfunction, including lower albumin and higher 
bilirubin in heart failure patients, are associated with 
poor prognosis [37]. Recent studies suggested that the 
liver plays a cardioprotective role in the experimental 
model of MI by secreting undefined protective 
proteins, indicating a new mechanism of protection 
by liver-derived hepatokines in heart failure [38]. The 
roles of the STAT3 signaling pathway in liver 
pathophysiology have been extensively investigated 
[39]. However, this study reported a novel role of 
hepatic STAT3 as a protective signaling pathway for 
the heart, a remote organ, in an endocrine manner 
post-MI. Of note, hepatic STAT3 ablation lead to 
aggravated cardiac dysfunction post-MI, but hepatic 
STAT3 was not activated in the post-MI setting 
(Figure 5D), suggesting that STAT3 is required for 
driving hepatic expression of proteins with 
cardioprotective activities in basal condition. 
Therefore, future secretome analysis of hepatocytes 
from liver-specific STAT3 KO mice may help identify 
additional targets from the STAT3 pathway for 
sustained cardiac protection.  
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Prior studies demonstrated increased levels of 
FGF21 in the circulation, liver, adipose tissue, and 
heart after MI [19, 32, 38 and 40]. We also detected 
higher plasma FGF21 in MI mice than in sham mice. 
However, systemic FGF21 deficiency [38] or 
liver-specific FGF21 deficiency from our study lead to 
the deterioration of post-MI cardiac function. Overall, 
we could speculate that endogenous FGF21 serves as 
an important cardio-protective mechanism in the MI 
setting. Furthermore, data from our study suggest 
that IL-22, as a therapeutic cytokine, further 
strengthens hepatic FGF21 production to protect the 
heart against MI. The regulation of hepatic FGF21 has 
been reported to be associated with several signaling 
pathways, including peroxisome proliferator- 
activated receptor (PPAR) α, PPARγ, activating 
transcription factor 4, cAMP-responsive element- 
binding protein H, farnesoid X receptor and liver X 
receptor under various conditions [41]. Our data 
suggest that hepatic STAT3 is indispensable for the 
induction of FGF21 following IL-22 administration.  
Previous studies in vitro have reported beneficial 
effects of FGF21 in cardiomyocytes by promoting 
energy supply and inhibiting oxidative stress and 
inflammation [42], all of which are crucial for cell 
survival. Our data demonstrated a beneficial effect of 
FGF21 on cardiomyocyte survival by inhibiting 
apoptosis under hypoxic conditions. Of note, our gene 
microarray and RT-PCR validation data suggest that 
FGF21 mainly upregulates several genes coding the 
key enzymes in cholesterol biosynthesis, including 
Acly (which catalyzes the formation of acetyl-CoA), 
Sqle (which catalyzes the conversion of farnesyl-PP to 
squalene), Lss (which catalyzes the conversion of 
(S)-2, 3-oxidosqualene to lanosterol), and Dhcr24 
(which catalyzes the reduction of the delta-24 double 
bond of sterol intermediates). It is widely accepted 
that hypoxic cardiomyocytes switch substrate 
utilization from fatty acids to glucose and 
downregulate lipid biosynthesis under hypoxic 
conditions to produce more energy with less oxygen 
consumption, and suppress energy consumption [43]. 
In line with this notion, we observed that the 
expression of genes involved in lipid metabolism 
decreased, while the expression of genes involved in 
glucose metabolism increased in hypoxic 
cardiomyocytes (Figure S12). On the other hand, we 
know that cholesterol itself and several intermediate 
metabolites in the biosynthesis of cholesterol are 
crucial for cell survival. Reducing intracellular 
cholesterol made cardiomyocytes susceptible to 
anoxia-induced damage [44]. As intermediate 
metabolites in the biosynthesis of cholesterol, 
squalene has been found to protect against oxidative 
DNA damage and apoptosis [45, 46]; elevated cellular 
lanosterol has been linked to decreased cell apoptosis 
under intermittent hypoxia conditions [47]. In 
summary, although the adaptive shift from lipid 
metabolism to glucose metabolism helps overcome 
the energy crisis, disturbed lipid metabolism can be 
deleterious to the ischemic heart. The disturbed 
cholesterol synthesis in hypoxic cardiomyocytes, 
which was partially restored by FGF21 treatment, 
may be related to the beneficial effect of FGF21 during 
myocardial ischemia.  
In conclusion, our findings presented a concept 
of inter-organ communication between the heart and 
the liver as an adaptive response to cardiac ischemic 
stress post-MI, and suggested a new perspective on 
the therapeutic potential of IL-22 and the hepatic 
STAT3-FGF21 axis in the setting of acute post-MI.  
Supplementary Material  
Supplementary materials and methods, figures and 
tables. http://www.thno.org/v08p4552s1.pdf  
Acknowledgments 
We thank Generon Corporation Ltd. (Shanghai, 
China) for providing recombinant mouse IL-22, Dr. 
Hongliang Li from Renmin Hospital of Wuhan 
University, China for providing αMHC-MerCreMer 
mice, Dr. Zhexiong Lian from University of Science 
and Technology of China for providing 
ALB-Cre/STAT3flox/flox mice, and Dr. Aimin Xu from 
University of Hong Kong, China for providing 
ALB-Cre/FGF21flox/flox mice. We also thank Ms. 
Chelsea Swallom from Brigham and Women's 
Hospital, USA for editorial assistance. 
Funding 
This work was supported by grants from the 
National Natural Science Foundation of China [No. 
81525003, 91639301, 81720108005 to X.C.; No. 
81200177, 81670361 to T.T.T.; No. 81600287 to Z.F.Z..; 
No. 81400364 to N.X.; No. 81500186 to S.F.N.], and 
National Institute of Health [HL123568, HL60942 to 
G.P.S.].  
Competing Interests 
Recombinant mouse IL-22 was provided by 
Generon (Shanghai, China) Corporation Ltd in the 
present study. 
References 
1. Fox KA, Steg PG, Eagle KA, et al. Decline in rates of death and heart failure in 
acute coronary syndromes, 1999-2006. JAMA. 2007;297: 1892-1900. 
2. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: 
pathophysiology and therapy. Circulation. 2000;101: 2981-2988. 
3. Velagaleti RS, Pencina MJ, Murabito JM, et al. Long-term trends in the 
incidence of heart failure after myocardial infarction. Circulation. 2008;118: 
2057-2062. 
4. Wolk K, Witte E, Witte K, Warszawska K, Sabat R. Biology of interleukin-22. 
Semin Immunopathol. 2010;32: 17-31. 
 Theranostics 2018, Vol. 8, Issue 16 
 
 
http://www.thno.org 
4562 
5. Bleicher L, de Moura PR, Watanabe L, et al. Crystal structure of the 
IL-22/IL-22R1 complex and its implications for the IL-22 signaling 
mechanism. FEBS Lett. 2008;582: 2985-2992. 
6. Dumoutier L, de Meester C, Tavernier J, Renauld JC. New activation modus of 
STAT3: a tyrosine-less region of the interleukin-22 receptor recruits STAT3 by 
interacting with its coiled-coil domain. J Biol Chem. 2009;284: 26377-26384. 
7. Guo X, Qiu J, Tu T, et al. Induction of innate lymphoid cell-derived 
interleukin-22 by the transcription factor STAT3 mediates protection against 
intestinal infection. Immunity. 2014;40: 25-39. 
8. Pickert G, Neufert C, Leppkes M, et al. STAT3 links IL-22 signaling in 
intestinal epithelial cells to mucosal wound healing. J Exp Med. 2009;206: 
1465-1472. 
9. Ki SH, Park O, Zheng M, et al. Interleukin-22 treatment ameliorates alcoholic 
liver injury in a murine model of chronic-binge ethanol feeding: role of signal 
transducer and activator of transcription 3. Hepatology. 2010;52: 1291-1300. 
10. Kong X, Feng D, Wang H, et al. Interleukin-22 induces hepatic stellate cell 
senescence and restricts liver fibrosis in mice. Hepatology. 2012;56: 1150-1159. 
11. Eggenhofer E, Sabet-Rashedi M, Lantow M, et al. RORgammat(+) 
IL-22-producing NKp46(+) cells protect from hepatic ischemia reperfusion 
injury in mice. J Hepatol. 2016;64: 128-134. 
12. Xu MJ, Feng D, Wang H, Guan Y, Yan X, Gao B. IL-22 ameliorates renal 
ischemia-reperfusion injury by targeting proximal tubule epithelium. J Am 
Soc Nephrol. 2014;25: 967-977. 
13. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases 
the innate immunity of tissues. Immunity. 2004;21: 241-254. 
14. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, 
FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000;1492: 
203-206. 
15. Berglund ED, Li CY, Bina HA, et al. Fibroblast growth factor 21 controls 
glycemia via regulation of hepatic glucose flux and insulin sensitivity. 
Endocrinology. 2009;150: 4084-4093. 
16. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects 
obesity in mice. Endocrinology. 2008;149: 6018-6027. 
17. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of 
diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 
2007;148: 774-781. 
18. Planavila A, Redondo I, Hondares E, et al. Fibroblast growth factor 21 protects 
against cardiac hypertrophy in mice. Nat Commun. 2013;4: 2019. 
19. Patel V, Adya R, Chen J, et al. Novel insights into the cardio-protective effects 
of FGF21 in lean and obese rat hearts. PLoS One. 2014;9: e87102. 
20. Tao L, Wang Y, Gao E, et al. Adiponectin: an indispensable molecule in 
rosiglitazone cardioprotection following myocardial infarction. Circ Res. 
2010;106: 409-417. 
21. Yang L, Zhang Y, Wang L, et al. Amelioration of high fat diet induced liver 
lipogenesis and hepatic steatosis by interleukin-22. J Hepatol. 2010;53: 339-347. 
22. Lin L, Amin R, Gallicano GI, et al. The STAT3 inhibitor NSC 74859 is effective 
in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene. 
2009;28: 961-972. 
23. Kaikita K, Hayasaki T, Okuma T, Kuziel WA, Ogawa H, Takeya M. Targeted 
deletion of CC chemokine receptor 2 attenuates left ventricular remodeling 
after experimental myocardial infarction. Am J Pathol. 2004;165: 439-447. 
24. Rainer PP, Hao S, Vanhoutte D, et al. Cardiomyocyte-specific transforming 
growth factor beta suppression blocks neutrophil infiltration, augments 
multiple cytoprotective cascades, and reduces early mortality after myocardial 
infarction. Circ Res. 2014;114: 1246-1257. 
25. Yan X, Shichita T, Katsumata Y, et al. Deleterious effect of the IL-23/IL-17A 
axis and gammadeltaT cells on left ventricular remodeling after myocardial 
infarction. J Am Heart Assoc. 2012;1: e004408. 
26. Zouggari Y, Ait-Oufella H, Bonnin P, et al. B lymphocytes trigger monocyte 
mobilization and impair heart function after acute myocardial infarction. Nat 
Med. 2013;19: 1273-1280. 
27. Hofmann U, Beyersdorf N, Weirather J, et al. Activation of CD4+ T 
lymphocytes improves wound healing and survival after experimental 
myocardial infarction in mice. Circulation. 2012;125: 1652-1663. 
28. Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of 
Stat3, identified through structure-based virtual screening, induces antitumor 
activity. Proc Natl Acad Sci U S A. 2007;104: 7391-7396. 
29. Enomoto D, Obana M, Miyawaki A, Maeda M, Nakayama H, Fujio Y. 
Cardiac-specific ablation of the STAT3 gene in the subacute phase of 
myocardial infarction exacerbated cardiac remodeling. Am J Physiol Heart 
Circ Physiol. 2015;309: H471-480. 
30. Radaeva S, Sun R, Pan HN, Hong F, Gao B. Interleukin 22 (IL-22) plays a 
protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor 
for hepatocytes via STAT3 activation. Hepatology. 2004;39: 1332-1342. 
31. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes 
responsible for antimicrobial defense, cellular differentiation, and mobility in 
keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36: 1309-1323. 
32. Liu SQ, Tefft BJ, Roberts DT, et al. Cardioprotective proteins upregulated in 
the liver in response to experimental myocardial ischemia. Am J Physiol Heart 
Circ Physiol. 2012;303: H1446-1458. 
33. Kim KH, Lee MS. FGF21 as a Stress Hormone: The Roles of FGF21 in Stress 
Adaptation and the Treatment of Metabolic Diseases. Diabetes Metab J. 
2014;38: 245-251. 
34. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a 
knowledge-based approach for interpreting genome-wide expression profiles. 
Proc Natl Acad Sci U S A. 2005;102: 15545-15550. 
35. Kuehnle K, Crameri A, Kalin RE, et al. Prosurvival effect of 
DHCR24/Seladin-1 in acute and chronic responses to oxidative stress. Mol 
Cell Biol. 2008;28: 539-550. 
36. Gassanov N, Caglayan E, Semmo N, Massenkeil G, Er F. Cirrhotic 
cardiomyopathy: a cardiologist's perspective. World J Gastroenterol. 2014;20: 
15492-15498. 
37. Ambrosy AP, Vaduganathan M, Huffman MD, et al. Clinical course and 
predictive value of liver function tests in patients hospitalized for worsening 
heart failure with reduced ejection fraction: an analysis of the EVEREST trial. 
Eur J Heart Fail. 2012;14: 302-311. 
38. Liu SQ, Roberts D, Kharitonenkov A, et al. Endocrine protection of ischemic 
myocardium by FGF21 from the liver and adipose tissue. Sci Rep. 2013;3: 2767. 
39. Wang H, Lafdil F, Kong X, Gao B. Signal transducer and activator of 
transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci. 2011;7: 
536-550. 
40. Zhang W, Chu S, Ding W, Wang F. Serum Level of Fibroblast Growth Factor 
21 Is Independently Associated with Acute Myocardial Infarction. PLoS One. 
2015;10: e0129791. 
41. Bae KH, Kim JG, Park KG. Transcriptional regulation of fibroblast growth 
factor 21 expression. Endocrinol Metab (Seoul). 2014;29: 105-111. 
42. Tanajak P, Chattipakorn SC, Chattipakorn N. Effects of fibroblast growth 
factor 21 on the heart. J Endocrinol. 2015;227: R13-30. 
43. Ford DA. Alterations in myocardial lipid metabolism during myocardial 
ischemia and reperfusion. Prog Lipid Res. 2002;41: 6-26. 
44. Bastiaanse EM, van der Valk-Kokshoorn LJ, Egas-Kenniphaas JM, Atsma DE, 
van der Laarse A. The effect of sarcolemmal cholesterol content on the 
tolerance to anoxia in cardiomyocyte cultures. J Mol Cell Cardiol. 1994;26: 
639-648. 
45. Warleta F, Campos M, Allouche Y, et al. Squalene protects against oxidative 
DNA damage in MCF10A human mammary epithelial cells but not in MCF7 
and MDA-MB-231 human breast cancer cells. Food Chem Toxicol. 2010;48: 
1092-1100. 
46. Saito K, Dubreuil V, Arai Y, et al. Ablation of cholesterol biosynthesis in neural 
stem cells increases their VEGF expression and angiogenesis but causes 
neuron apoptosis. Proc Natl Acad Sci U S A. 2009;106: 8350-8355. 
47. Zhen YQ, Wu YM, Sang YH, et al. 2,3-Oxidosqualene cyclase protects liver 
cells from the injury of intermittent hypoxia by regulating lipid metabolism. 
Sleep Breath. 2015;19: 1475-1481. 
